- Knowledge center
The use of biomarkers is the cornerstone of effective precision medicine. RNA forms an excellent source of biomarkers to enable early disease detection, assessment of prognosis, monitoring patient response to therapy or selecting the right treatment for the right patient. Biogazelle has broad experience in the design and implementation of RNA biomarker discovery studies. Through the combination of RNA sequencing and advanced model building, our biomarker development platform aims at establishing a complex biomarker, integrating gene expression measurements and clinical parameters. Such a complex biomarker generally outperforms single biomarkers for classification purposes.
Our biomarker development platform can handle a variety of sample types, including whole blood, plasma, serum, FFPE tissue and PBMCs, allowing us to start from retrospectively collected samples. Following the initial discovery, Biogazelle supports the further development of the biomarker into a clinical-grade test, offering in this way an end-to-end solution from RNA biomarker discovery to the development of a research-use-only (RUO) or clinical trial biomarker assay.